Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia

Published:2015-01-21 Issue:8 Volume:56 Page:2326-2330
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Chantepie Sylvain P.,Reboursiere Emilie,Mear Jean-Baptiste,Gac Anne-Claire,Salaun Veronique,Benabed Khaled,Cheze Stéphane,Johnsonansah Hyacinthe,Macro Margaret,Vilque Jean-Pierre,Reman Oumedaly

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.986478

Reference31 articles.

1. Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse

2. Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG

3. Outcome of older patients with acute myeloid leukemia in first relapse

4. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

5. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience;Medicina;2023-03-02

2. The promise and perils of immunotherapy;BLOOD ADV;2021

3. The promise and perils of immunotherapy;Blood Advances;2021-09-28

4. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively;Cancer Medicine;2021-06-24

5. Efficacy, Safety, and Tolerance of Gemtuzumab Ozogamicin Combined with FLAG/FLAG-Ida or Azacitidine in Relapsed/Refractory Acute Myeloblastic Leukemia;Clinical oncohematology;2021